Iterum Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on November 10, 2022
Iterum Therapeutics plc (Nasdaq: ITRM) announced that it will release its third quarter 2022 financial results on November 10, 2022, before U.S. market opening. A conference call will follow at 8:30 a.m. ET for discussing these results and business updates. The Company is progressing its lead product, sulopenem, a novel anti-infective in Phase 3 clinical development, demonstrating effectiveness against multi-drug resistant pathogens. Iterum has secured QIDP and Fast Track designations for sulopenem across seven indications.
- Sulopenem's Phase 3 development indicates potential for strong future revenue.
- Qualified Infectious Disease Product (QIDP) and Fast Track designations may enhance market positioning.
- None.
DUBLIN, Ireland and CHICAGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2022 financial results before the open of the U.S. financial markets on Thursday, November 10, 2022. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business.
To access the call please dial 844-200-6205 (domestic) or 929-526-1599 (international) and refer to Access Code 819977. To pre-register for this call, please go to the following link: https://events.q4inc.com/attendee/226647936. The audio webcast can be accessed under “Financials & Filings” in the Investors section of the Company’s website at www.iterumtx.com following the call.
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is currently advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit http://www.iterumtx.com.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com
FAQ
When will Iterum Therapeutics release its third quarter 2022 financial results?
What is the focus of Iterum Therapeutics?
What is sulopenem and its significance for Iterum Therapeutics?
